Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease.

SUMMARY: We assessed the safety and surrogate markers' effect of acemannan as an adjunctive to antiretroviral therapy among patients with advanced HIV disease receiving zidovudine (ZDV) or didanosine (ddI) in a randomized, double-blind, placebo-controlled trial of acemannan (400 mg orally four times daily). Eligible patients of either sex had CD4 counts of 50-300/microl twice within 1 month of study entry and had received 26 months of antiretroviral treatment (ZDV or ddI) at a stable dose for the month before entry. CD4 counts were made every 4 weeks for 48 weeks. P24 antigen was measured at entry and every 12 weeks thereafter. Sequential quantitative lymphocyte cultures for HIV and ZDV pharmacokinetics were performed in a subset of patients. Sixty-three patients were randomized. All were males (mean age 39 years). The mean baseline CD4 counts were 165 and 147/microl in the placebo and acemannan groups, respectively; 90 percent of the patients were receiving ZDV at entry. Six patients in the acemannan group and five in the placebo group developed AIDS-defining illnesses. There was no statistically significant difference between the groups at 48 weeks with regard to the absolute change or rate of decline at CD4 count. Among ZDV-treated patients, the median rates of CD4 change (ACD4) in the initial 16 weeks were - 121 and - 120 cells per year in the placebo and acemannan groups, respectively ( p = 0.45), ACD4 from week 16 to 48 was 0 and - 61 cells per year in the acemannan and placebo groups (p = .11), respectively. There was no statistical difference between groups with regard to adverse events, p24 antigen, quantitative virology, or pharmacokinetics. Twenty-four patients, 11 receiving placebo and 13 receiving acemannan, discontinued study therapy prematurely, none due to serious adverse reactions. Our results demonstrate that acemannan at an oral daily dose of 1600 mg does not prevent the decline in CD4 count characteristic of progressive HIV disease. Acemannan showed no significant effect on p24 antigen and quantitative virology. Acemannan was well tolerated and showed no significant pharmacokinetic interaction with ZDV.

Left-right asymmetry in two types of soccer kick.

The ability to kick with both feet is regarded as a desirable skill in high level soccer players; however, most players display a dominance of kicking ability on one side. This study investigated the characteristics of asymmetry in two types of soccer kick. A low drive and a chip kick from both the left and right foot of 12 élite junior soccer players were analysed. Kick velocity, kick accuracy, position of the plant foot from the ball centre, and time from foot plant to ball contact were measured for each kick. Knee extension and flexion strength were also determined for each leg at 60 degree s-1, 180 degree s-1 and 240 degrees s-1 on a Cybex II Isokinetic Dynamometer. A single factor repeated measures analysis of variance was applied to velocity, plant foot position and timing parameters to compare between sides and between shots. chi 2 analysis was used to compare accuracy between shots and between sides, and a paired Student's t test was used to compare strength parameters between sides. Pearson's product moment correlation analysis was used to examine the relationship between velocity and both leg strength and the time from foot plant to ball contact. Significance was set at P < or = 0.05. The results showed that this group had strength dominance at all speeds tested on the right side and better drive kick performance with their right leg as determined by mean(s.d.) velocity (79(6) versus 66(8) km h-1) and accuracy (66.6% versus 33.3%). There was no difference in these parameters between sides for chip kicks.(ABSTRACT TRUNCATED AT 250 WORDS)

Yersiniosis in free-ranging muskoxen on Banks Island, Northwest Territories, Canada.

Sixty-seven muskox (Ovibos moschatus) carcasses, 53 skeletal remains and two sick muskoxen were seen during an aerial survey of the Thomsen River region, northern Banks Island, Northwest Territories, Canada in late July 1986. Complete necropsies were performed on 29 muskoxen estimated to have died within the previous 3 to 5 days. Twenty were diagnosed with acute yersiniosis due to Yersinia pseudotuberculosis serotype 1B and were in excellent body condition. A diagnosis could not be made on seven animals due to marked autolysis; however, these muskoxen also were in excellent body condition. The remaining two were aged, emaciated muskoxen. This report describes the first occurrence of yersiniosis in free-ranging muskoxen and the first documentation of large scale mortality due to this disease in a free-ranging population of wild ungulates.

An anthropometric analysis of elite Australian track cyclists.

An anthropometric analysis was conducted on 35 elite male Australian track cyclists having a mean age of 22.6 years and who had been competing on average for 9 years. The relationship of anthropometric parameters to both bicycle saddle height and cycling performance was also investigated. Subjects were allocated, for purposes of comparison, to an endurance or sprint group on the basis of their competitive event. The group members in total were ectomorphic mesomorphs of height 178 +/- 4.8 cm and weight 72.5 +/- 6.6 kg on average. Percentage of saddle height to lower limb length averaged 99 +/- 1.6%, and significant correlations existed between strength and both body mass (r = 0.57) and thigh girth (r = 0.55). No significant correlation was seen between any anthropometric parameter and performance in an individual event. Cyclists in the spint group were heavier (76.2 +/- 7.4 vs. 70.0 +/- 4.7 kg, P less than 0.01) and stronger (258 +/- 44.4 vs. 216 +/- 30.5 Nm, P less than 0.01), and had larger chest (98.2 +/- 6.2 vs. 92.4 +/- 2.9 cm, P less than 0.01), arm (33.0 +/- 2.2 vs. 30.7 +/- 1.6 cm, P less than 0.01), thigh (57.5 +/- 3.4 vs. 54.3 +/- 2.5 cm, P less than 0.01) and calf girths (37.8 +/- 1.7 vs. 36.2 +/- 1.9 cm, P less than 0.05) than cyclists in the endurance group. They were also more mesomorphic (5.3 +/- 0.7 vs. 4.7 +/- 0.8, P less than 0.05) and less ectomorphic (2.3 +/- 0.9 vs. 2.9 +/- 0.6, P less than 0.05) than the endurance cyclists.